In a regulatory filing, Amneal Pharmaceuticals (AMRX) director Gautam Patel disclosed the sale of 62,590 class A common shares of the company on January 8 at a price of $8.01 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX: